U.S., Oct. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07874880) titled 'MTX-531-001 Phase 1 Study in Advanced Solid Tumors' on Oct. 07.
Brief Summary: This is a first-in-human, Phase 1, open-label study evaluating MTX-531, an investigational dual EGFR/PI3K inhibitor, in adults with advanced solid tumors. The study will evaluate the safety and tolerability of MTX-531, determine the maximum tolerated dose and recommended Phase 2 dose, and assess how the drug is processed by the body and its preliminary anti-tumor activity.
Study Start Date: Oct. 20
Study Type: INTERVENTIONAL
Condition:
Solid Tumors (Phase 1)
HNSCC
Endometrial Cancer
Her2-negative Metastatic Breast Cancer
Pan-RAS and BRAF Wild-type Adv...